Clinical Trials Browser

Phase 1/2 × Has results × Leukemia, Myelomonocytic, Juvenile × Clear all

Leukemia, Myelomonocytic, Juvenile

NCT00423514 2022-12-27

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Phase 1/2 Completed

70 enrolled 26 charts

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT00609739 2017-12-28

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Phase 1/2 Terminated

1 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myelomonocytic, Juvenile

Clinical Trials

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation